Antibodies News and Research

RSS

Chemicals in packaged food and textiles linked to low immunity in kids: Study

According to researchers children exposed to chemicals from food packaging and textile products may have compromised immune systems. They found kids with more perfluorinated compounds, or PFCs, in their blood stream were less likely to respond to routine vaccines.

26 Jan 2012

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson today announced sales of $16.3 billion for the fourth quarter of 2011, an increase of 3.9% as compared to the fourth quarter of 2010. Operational sales increased 4.0% and the negative impact of currency was 0.1%.

24 Jan 2012

Duke team creates vaccine adjuvant of nanoparticles that target lymph nodes

Researchers at Duke University Medical Center have created synthetic nanoparticles that target lymph nodes and greatly boost vaccine responses, said lead author Ashley St. John, Ph.D., a researcher at Duke-NUS Graduate Medical School.

23 Jan 2012

Study describes new pharmacological resistance to colon cancer

Doctors and researchers of Hospital del Mar and its research institute, the IMIM, have lead a study describing a new pharmacological resistance to cancer. This new mechanism is a mutation in an oncogene called EGFR (epidermal growth factor receptor) causing resistance to treatment using a drug called cetuximab, a monoclonal antibody which specifically attacks the EGFR.

23 Jan 2012

FDA allows marketing of Stratify JCV Antibody ELISA test for PML

Today, the U.S. Food and Drug Administration allowed marketing of the first test to help determine the risk for a rare brain infection called progressive multifocal leukoencephalopathy (PML) in people using the drug Tysabri (natalizumab) to treat multiple sclerosis (MS) or Crohn's disease.

21 Jan 2012

FDA approves product label change for Biogen Idec's TYSABRI to treat MS

Today Biogen Idec and Elan Corporation, plc announced that the U.S. Food and Drug Administration (FDA) has approved a product label change for TYSABRI that will help enable individual benefit risk assessment for patients with multiple sclerosis.

21 Jan 2012

NIEHS study: 32M people in the U.S. have autoantibodies

A recent study conducted by the National Institute of Environmental Health Sciences (NIEHS), an agency of the National Institutes of Health (NIH), shows that 32 million people in the United States have autoantibodies, the most common of which are antinuclear antibodies.

19 Jan 2012

Soligenix reports results from long-term stability studies of SGX204 anthrax vaccine

Soligenix, Inc., a development stage biopharmaceutical company, announced today results from long-term stability studies of its proprietary DNI anthrax rPA subunit protein vaccine, known as SGX204.

19 Jan 2012

Innovative computer algorithm identifies clinically prognostic marker for cancer

Researchers at the Stanford University School of Medicine have used an innovative mathematical technique to find markers that effectively predict how deadly a cancer will be. The discovery, which in this case concerned bladder cancer, could lead to faster, less expensive and more accurate analysis of cancer risk and better treatment of the disease.

18 Jan 2012

Pevion announces further data from clinical study of PEV7 therapeutic Candida vaccine

Pevion Biotech AG today announced further data from the ongoing clinical study of its therapeutic Candida vaccine PEV7, demonstrating the generation of specific and functional B cell memory in 100% of vaccinees. Furthermore, the results again confirm the capability of Pevion's second generation virosomal vaccine platform to induce strong and long-lasting immunity in humans against otherwise weak antigens .

17 Jan 2012

Researchers discover HS1.2 enhancer as the cause of SLE

A "genetic accelerator" is responsible for the most severe cases of Lupus (systemic lupus erythemathosus), an autoimmune disease: the accelerator, called enhancer HS1.2, speeds up the activity of some critical genes of the immune system involved in the disease.

17 Jan 2012

Hormone that burns energy discovered

Boston scientists have found a hormone that is secreted by muscles during exercise and boosts the amount of energy the body burns. This hormone – irisin – could be the first step in development of new drugs for obesity, diabetes, and other diseases feel researchers. A Boston startup company, Ember Therapeutics, has already licensed the technology and is working to develop a form of the hormone that could be used as a drug that would mimic some of the benefits of exercise.

16 Jan 2012

IBM's non-contact, microfluidic, silicon probe minimizes patient discomfort

IBM scientists have developed a flexible, non-contact microfluidic probe made from silicon that can aid researchers and pathologists to investigate critical tissue samples accurately for drug discovery and disease diagnostics.

13 Jan 2012

New imaging probes can non-invasively detect breast cancer lymph node metastasis

Using two cell surface markers found to be highly expressed in breast cancer lymph node metastasis, researchers at Moffitt Cancer Center, working with colleagues at other institutions, have developed targeted, fluorescent molecular imaging probes that can non-invasively detect breast cancer lymph node metastasis.

13 Jan 2012

African bats have antibodies that neutralize deadly Hendra virus

A new study on African bats provides a vital clue for unravelling the mysteries in Australia's battle with the deadly Hendra virus.

13 Jan 2012

$Merrimack commences MM-151 Phase 1 trial in refractory advanced solid tumors$

Merrimack commences MM-151 Phase 1 trial in refractory advanced solid tumors

Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor.

11 Jan 2012

Study confirms safety and effectiveness of rAHF-PFM in managing hemophilia A

A Rush University Medical Center led international research team has announced that a treatment to prevent bleeding episodes in children with hemophilia A also is effective for adolescents and adults.

10 Jan 2012

MAL3-101 appears to have potent anti-tumor effects on multiple myeloma

A new study from SUNY Downstate Medical Center in Brooklyn, New York, shows that MAL3-101, a recently developed inhibitor of the heat shock protein 70 (Hsp70), appears to have potent anti-tumor effects on multiple myeloma, a bone marrow cancer.

10 Jan 2012

Enrollment complete in Diamyd Phase II study for type 1 diabetes

A total of 50 children aged four and older with a high risk of developing type 1 diabetes have been enrolled in a researcher-initiated Phase II study, DiAPREV-IT, with Diamyd Medical's diabetes vaccine Diamyd. The study is thus fully recruited.

9 Jan 2012

New U.S. patent covers key element of Xencor's Xtend half-life prolongation technology

Xencor, Inc., a company using its proprietary Protein Design Automation (PDA) platform technology to engineer next-generation antibodies, announced today that the U.S. Patent and Trademark Office has issued Xencor a broad patent covering optimized monoclonal antibody variants and their application for extending in vivo half-life of antibodies.

7 Jan 2012